What it's for (Indications)
- Hexavalent vaccines, such as DTaP-IPV-Hib-HepB, are indicated for active primary and booster immunization of infants and toddlers against six infectious diseases: diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated), invasive diseases caused by Haemophilus influenzae type b (Hib), and hepatitis B.
- This comprehensive immunization strategy is crucial for reducing the incidence and severity of these potentially life-threatening pediatric illnesses, aligning with national and international immunization schedules to confer broad protective immunity early in life.
- The vaccine aims to prevent infections by stimulating the immune system to produce antibodies against the specific antigens of each included pathogen.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage for Hexaxim and similar hexavalent vaccines is a single 0.5 mL dose administered by intramuscular injection. The primary vaccination schedule generally consists of two or three doses given at intervals determined by national immunization programs, usually commencing from two months of age. For instance, a common schedule may involve doses at 2, 4, and 6 months of age, or 3, 5, and 11 months, depending on local guidelines and the specific vaccine formulation. A booster dose may be recommended later in childhood to sustain long-term immunity against these diseases. Adherence to the recommended schedule is paramount for optimal immunogenicity and protective efficacy. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects are generally mild and transient, primarily local reactions at the injection site such as pain, redness, and swelling, often resolving within 24-48 hours.
- Systemic reactions may include fever (typically low-grade), irritability, loss of appetite, somnolence, abnormal crying, vomiting, and diarrhea.
- Less common but more severe reactions can include extensive limb swelling, prolonged inconsolable crying (lasting several hours), febrile seizures, or hypotonic-hyporesponsive episodes (HHE).
- Serious allergic reactions, such as anaphylaxis, are exceedingly rare but require immediate medical attention.
- Parents and caregivers should be advised on managing these side effects and when to seek medical advice.
Serious Warnings
- Black Box Warning: While hexavalent vaccines like DTaP-IPV-Hib-HepB do not carry a formal FDA Black Box Warning, several serious safety warnings and precautions are critically important for healthcare providers to consider. These include, but are not limited to, the immediate availability of epinephrine and other medical equipment to manage potential anaphylactic reactions, which, though rare, can be life-threatening. A history of Guillain-Barré Syndrome or brachial neuritis following a previous tetanus toxoid-containing vaccine should be carefully evaluated, weighing the potential benefits against the risks. There is an increased risk of apnea and the need for respiratory monitoring in infants born very prematurely (at or before 28 weeks of gestation) for 48-72 hours after vaccination. Decisions regarding future doses of pertussis-containing vaccine should be made cautiously if a hypotonic-hyporesponsive episode or persistent, inconsolable crying occurred within 48 hours, or if convulsions occurred within 3 days following a prior dose.
- Prior to administration, it is crucial to assess the patient's medical history for any contraindications or specific precautions.
- Vaccination should be postponed in individuals with acute, severe febrile illness; however, minor infections with or without low-grade fever are not typically a contraindication.
- Special caution is advised for infants with a history of apnea or respiratory immaturity, particularly those born very prematurely (<28 weeks of gestation), due to the potential risk of post-vaccination apnea, requiring appropriate monitoring for 48-72 hours.
- Individuals with bleeding disorders or thrombocytopenia should receive the vaccine intramuscularly with caution to minimize the risk of hematoma.
- Syncope (fainting) can occur after any vaccination, particularly in adolescents and young adults, emphasizing the need for appropriate precautions to prevent injury.
How it Works (Mechanism of Action)
The DTaP-IPV-Hib-HepB vaccine is a combination vaccine designed to elicit active immunity against six distinct pathogens simultaneously. It achieves this by presenting purified antigens from each organism to the immune system. The diphtheria and tetanus components are toxoids, inactivated bacterial toxins that stimulate antitoxin antibody production. The pertussis component comprises acellular antigens (e.g., pertussis toxoid, filamentous hemagglutinin) that induce protective immunity against whooping cough. Polio protection is conferred by inactivated poliovirus types 1, 2, and 3. The Hib component contains Haemophilus influenzae type b capsular polysaccharide conjugated to a carrier protein, enhancing immunogenicity in infants. The Hepatitis B component is recombinant HBsAg. These antigens stimulate humoral (antibody-mediated) and cellular immune responses, leading to the development of specific memory cells that provide long-term protection against future infections.